Approaches to determine whether one transplant-related therapy is better than another include: (1) using experimental data, such as those from randomized controlled trials (RCTs); (2) using observational data, such as those from observational databases (ODBs) and (3) using conclusions from the structured quantification of expert opinion based on a consideration of evidence from RCTs, ODBs and other sources. Large RCTs are widely and appropriately regarded as the gold standard of clinical investigation. However, data from large RCTs are rarely available for transplant-related therapy questions. We discuss some of the limitations of RCTs in the transplant setting often including small size and short follow-up. These limitations are only partly solved by meta-analyses of RCTs. Data from high-quality ODBs are not only often useful in this setting but also have limitations. Biases may be difficult or impossible to identify and/or adjust for. However, ODBs have large numbers of diverse subjects receiving diverse therapies and analyses that often give answers more useful to clinicians than RCTs. Side-by-side comparisons suggest analyses from high-quality ODBs often give similar conclusions to meta-analyses of highquality RCTs. Meta-analyses combining data from RCTs and ODBs are sometimes appropriate. Quantitation of expert opinion, when of high quality, is also useful: experts rarely disagree under precisely defined circumstances and their consensus conclusions are often concordant with results of high-quality RCTs and ODBs. We suggest increased use of ODBs and expert opinion as reliable and effective ways to determine relative efficacies of new therapies in transplant settings.
trials; expert opinion 'If a man will begin with certainties, he shall end in doubts, but if he will be content to begin with doubts, he shall end in certainties'.
Francis Bacon
There are several approaches to determine whether a new therapy option is reliable and effective, including experimental and observational studies and quantitation of expert opinion. Each approach has advantages and disadvantages. Large randomized controlled trials (RCTs) are usually (and rightly) considered the gold standard for comparing therapies. But are there other approaches that can sometimes get to the correct answer more quickly and efficiently? Here, we consider the benefits and limitations of two alternate approaches to answering clinical questions in the transplant setting: (1) observational databases (ODBs) and (2) structured quantification of expert opinion based on evidence from RCTs, ODBs and other sources.
RCTs
Features Several types of experimental study are used to compare therapies. Most highly regarded are RCTs in which subjects are randomly assigned to receive one or more alternative therapies. The critical advantage of RCTs over other experimental approaches is that randomization ensures comparability on the average of subjects in the therapy arms being studied. This contrasts with nonrandomized studies in which regression techniques are often used to adjust for known prognostic factors. Randomized trials provide balance on known and unknown prognostic factors and eliminate the problem of selection bias where certain subjects are more or less likely to get certain treatments than others. Another advantage of RCTs is that the data are collected prospectively providing high-quality, well-defined assessment of outcomes as a basis for comparison. Because of these features, RCTs that identify a benefit for a new therapy at a statistically significant level are credible to clinicians. Because there is little debate regarding the advantages of large, properly performed RCTs in comparing alternate therapies, our focus is on their limitations.
Problems
Volume. Results of RCT are most convincing when they have large numbers of subjects. This is rarely so in RCTs of transplant-related issues. For example, an appropriately powered (90% power) RCT designed to detect a 10% difference in outcome of autotransplants vs chemotherapy in persons with AML in first remission requires about 1000 subjects. No RCT of even 300 subjects is reported. This contrasts, for example, with the Center for International Blood and Marrow Research ODB that contains data on 410 000 subjects with AML in first remission. Another limitation of RCTs is the small volume of transplants at any center. RCTs are most easily done when one or a few centers are involved. (This may be changing because of the Center for International Blood and Marrow Research (CIBMTR) Clinical Trials Network). More than 50% of the 169 centers reporting to the CIBMTR perform fewer than 30 transplants per year and only 30 centers perform more than 100 per year. Moreover, transplants performed even at the large centers are heterogeneous with regard to age, disease and disease stage among other variables. Another issue is the slow rate of accrual to RCTs. These trials often take 5-10 years from inception to publication. Consequently, the therapies being compared are frequently not of current interest. Proponents of each therapy being compared often discount results of the late published RCT claiming that techniques and technologies have changed and the conclusions of the trials are no longer relevant. This problem of delayed relevance is compounded by the need for long follow-up in some studies.
Treatment definition in multi-center trials. Clinical trialists are familiar with obstacles in organizing multi-center RCTs. Although centers may agree, for example, to compare conventional to less-intensive allotransplants, they may not agree on what constitutes less intensive. These disagreements typically lead to two solutions. The first is to agree on a common, less-intensive regimen. This results in uniformity in trial conduct but limits generalizability of the conclusion; a similar conclusion may not apply to other less-intensive regimens (see below). The second solution is to allow each center to do a less-intensive allotransplant in any manner it prefers. This makes conclusions more generalizable but introduces variability uncontrolled by randomization. For example, what if different less-intensive allotransplant approaches are of different efficacy? Then the impact of an effective therapy may be negated by mingling it with ineffective therapies. There are potential solutions to some of these problems; none is perfect. Although this limitation applies to all data analyses, it is of greater concern in the context of RCTs where numbers of subjects receiving each therapy are small compared with large ODBs (see below).
Generalizability. Although there is considerable advantage of having comparable subjects in therapy arms in large RCTs, there are several limitations to extrapolating conclusions from these trials to clinical practice. For example, most RCTs precisely specify study entry criteria and therapy parameters. Although precise study entry criteria ensure comparability of subjects in the therapy arms, this limits applicability of the study conclusions. Subjects on RCTs are often different from typical persons with the disorder being considered (younger, fitter and so on). It is common for entrants into RCTs to represent o10% of the universe of potential therapy candidates.
1 It may not be appropriate to assume that the benefit of treatment translates to subjects with features different than the study entrants. For example, conclusions of a trial of subjects 18-50 years should not be assumed applicable to younger or older persons. The heterogeneity of subjects in ODBs is considerably greater than those in RCTs, reflecting the potential for more generalizable results.
Consistency of treatment effect. Although RCTs may find a benefit of one therapy over another, the conclusion applies to a cohort of subjects but not necessarily to all subjects in the cohort. Put differently, the benefit of the new therapy may not be uniformly distributed among subjects in a cohort of an RCT: some subjects may benefit, whereas others may be harmed. 2 Thus, although results of RCT inform the clinician how to treat a cohort of subjects, these data may not translate to persons for whom the clinician must decide which therapy to recommend.
3 Moreover, it is sometimes possible to predict pre-randomization who may benefit from or be harmed based on subject characteristics. This indicates an interaction with treatment, in which subjects with different characteristics respond differently to therapy. These interactions may be detected when large ODBs are used; RCTs are rarely powered to detect interactions. As we shall see, the same limitation of generalizability applies even more to meta-analyses of RCTs. 4 Contradictory outcomes. Because of the substantial theoretical advantages of RCTs over alternate approaches, RCTs are regarded as the gold standard for determining whether a new therapy is better than a current therapy. The question is: how well do RCTs perform in real-world settings? Considerable data indicate that RCTs test seemingly similar clinical questions sometimes produce discordant answers. 5 Consider two trials testing survival after consolidation chemotherapy or BM autotransplants in adults with AML in first remission. One trial of 254 subjects reported a significant disease-free survival benefit for autotransplants (effect size, 1.60 [1.15-2.23]). 6 However, a second trial of 233 subjects found no survival difference (effect size, 1.00 [0.70-1.43]). 7 How would a clinician know which conclusion is correct (if either)? The finding of disparate outcomes of highly-cited, initially favorable RCTs is not uncommon. Below we discuss whether metaanalyses are useful in resolving seemingly disparate results of RCTs. 8 Because randomization provides an unbiased assessment of the treatment-effect for that specific study, the most likely reason for RCTs with disparate outcomes is that the trials are not really comparable. For example, assignment to chemotherapy vs autotransplant was at different intervals postremission. Moreover, different drugs were used in the chemotherapy arms of several trials along with different pretransplant conditioning regimens. Because of this variability it is reasonable to expect different outcomes.
Careful consideration of the possible impact of this variability is needed to determine whether it is reasonable to combine these trials in a meta-analysis. We discuss another example of disparate results of RCTs below when we analyze whether blood or BM grafts are better.
Another potential reason for disparate outcomes of RCTs relates to blinding or randomization concealment. Failure to use adequately concealed random allocation can distort the apparent effects of a treatment in either direction causing the effects to seem larger or smaller than they really are. The size of these distortions can be as large as or larger than the size of the effects that are to be detected. 9 Use of biological assignment rather than randomization, as is sometimes done in transplant studies, also raises potential for enrollment bias to impact study results. 10 As we discussed above, most physicians want a generic rather than specific answer to the question whether autotransplants are better than chemotherapy in persons with AML in first remission. They are unlikely to get it from this compilation of RCTs as each trial tests a different autotransplant strategy and a different chemotherapy strategy. This limitation can be overcome if the metaanalysis shows no significant interaction between outcome and treatment. It is also important to consider that we rarely have more than one or two 'large' RCTs to evaluate in the transplant field. Were there only data from one RCT there would be a substantial likelihood that results would be inconclusive or incorrect for a small magnitude therapy-effect.
Biases in interpreting disparate results of RCTs
Confirmation bias and attitude polarization. How do people deal with disparate information such as contradictory results of RCTs? This issue is intimately related to the concept of confirmation bias, a tendency to search for or interpret new information in a way that confirms one's preconceptions and avoids information and interpretations that contradict prior beliefs. Confirmation bias is extensively studied by psychologists. In a classic experiment, students from Dartmouth and Princeton universities were shown clippings of the contentious 1951 DartmouthPrinceton football game and asked note every instance of cheating. Students from each university were convinced the other side had cheated more. 11 Another study involved students who favored or opposed capital punishment. The students were shown two studies: one suggesting executions reduce subsequent murders and the other doubted that. 12 Whatever their stance, the students judged the study supporting their position well conducted and persuasive and the other study profoundly flawed. Although a balanced analysis of the studies suggests no strong conclusions should be drawn, the opposite happened: students accepted evidence conforming to their original view, rejecting contrary evidence. This concept is referred to as attitude polarization. These data suggest that clinicians reviewing data from contradictory RCTs are more likely to believe those confirming their prejudices and reject contradictory data. Experience suggests this is, unfortunately, so. Many readers will be aware of Murphy's Law of Research: enough research will tend to support your theory. Francis Bacon enumerated this concept in 1620: 'The human understanding when it has once adopted an opiniony draws all things else to support and agree with it. And though there be a greater number and weight of instances to be found on the other side, yet these it either neglects and despisesy in order that by this great and pernicious predetermination the authority of its former conclusions may remain inviolate'. 13 Why do clinician fall prey to confirmation bias? Recent data suggest a physiological basis. For example, a study in 30 men was carried out just before the 2004 US presidential election; 15 men described themselves as strong Republicans and the remaining 15 as strong Democrats.
14 Subjects were asked to assess contradictory statements by George W Bush and John Kerry while having a functional magnetic resonance imaging scan. The scans showed that the part of the brain associated with reasoning (dorsolateral prefrontal cortex) was not involved when assessing the candidates' statements whereas the most active regions of the brain were those involved in processing emotions (orbitofrontal cortex), conflict resolution (anterior cingulate cortex) and making judgments about moral accountability (posterior cingulate cortex).
A related but distinct issue is the impact of the setting in which individuals make decisions on their choices summarized in Thaler and Sunstein. 15 For example, how much people eat depends greatly on the size of the dinner plate rather than the amount of food on the plate. 16 Likewise, how much people drink depends more on the characteristics of the glass than on the volume in it. And what magazines people buy depends on what's displayed at the supermarket checkout counter. In a well-known experiment in experimental psychology, subjects' soup consumption were shown to be more strongly correlated with the behavior of other diners (disguised experimenters) than to any other variable, like hunger or portion size. Thus, what peoples' peers think or do has a substantial impact on a person's actions and decisions. These setting biases also likely apply to decisions with more serious consequences, like results of which RCTs to accept. Examples include meeting and/or publication venue, authorship, trial site(s) and the like.
Bias of scale. Another important bias in interpreting results of RCTs relates to sample size. One might assume clinicians give greater weight to results of RCTs of many vs few subjects. However, this may not be so. Substantial data from psychology studies suggests people are more influenced by data about few individuals than many. 17 This is because emotion is an important aspect of decision-making. For example, people typically have a higher emotional response to learning about one starving African child than they do when learning about a famine killing millions. Joseph Stalin expressed this sentiment concisely: 'One man's death is a tragedy. A thousand deaths is a statistic'. The consequence of this interplay between sample size and emotion is that clinicians may place greater weight on results of a small RCT, especially when its conclusion is concordant with their pre-RCT prejudice, than a larger RCT that is discordant with their pre-RCT prejudice. This devaluation of emotion with increasing sample size has even greater impact on how clinicians evaluate data from very large ODBs (see below).
Can the limitations of RCT be solved by meta-analyses?
Meta-analyses combine results of several studies that address a set of related research hypotheses. They are often highly regarded in the hierarchy of clinical evidence and are frequently cited. [18] [19] [20] Meta-analyses can be applied to data from RCTs, ODBs or both. Here, we focus on meta-analyses of data from RCTs; use with ODBs alone or combined with RCT is discussed below.
Conclusions from meta-analyses are widely used to determine relative efficacy of a new therapy, especially when it is difficult to perform large RCTs. Their predominant use in the context of medical therapies is to increase power when effect size is small and individual studies lack sufficient power to detect an effect size of this magnitude. Meta-analyses are used to adjudicate disparate results of RCTs but this is not their primary purpose.
There are several intrinsic weaknesses of meta-analyses including the pooling of biases of the included studies, biases introduced by the process of selecting RCTs for inclusion and heterogeneity between the RCTs included. Publication bias is an important limitation of meta-analyses: RCTs with favorable outcomes are more likely to be published than those with unfavorable outcomes. A relevant example is an analysis of publications regarding prognostic variables in cancer: 90-95% of all reports in 2005 were positive. 21 Recent reviews find about 50% of meta-analyses were affected by publication bias. Addition of the unreported studies to the meta-analysis substantially changed the conclusion in 10-20%. 22, 23 This deficiency can be partly adjusted for by sensitivity analyses. Also, conclusions of meta-analyses may be influenced by funding source 24 and other variables. Several studies compared whether conclusions of meta-analyses are concordant with those of large clinical trials with disparate conclusions. For example, in one study that compared the magnitude and uncertainty of treatment effects found discordances in 10-23% of clinical settings. 8 Applicability Meta-analyses of RCTs are most useful in analyzing transplant therapies when the clinical trials' design and therapies (including doses and schedules) are quite similar or identical. However, variations in these introduce heterogeneity that can be approached, but not solved, using a random-effects model. In the example of chemotherapy vs autotransplants for AML in first remission discussed above, there are substantial differences between the six RCTs with regard to interval in remission when randomization was done, chemotherapy used to achieve remission, postremission chemotherapy (if any), chemotherapy postrandomization (if any), pretransplant conditioning regimen and number of autotransplants. We can test for the effect of these differences on the treatmenteffect by using a test of heterogeneity. In this case, there is no significant difference between the treatment effects across centers (P ¼ 0.38), and in fact the estimate of the overall treatment effect across studies (1.24) is contained in each study's confidence interval for the treatment effect. If we think any one or more of these variables is interacted with treatment or if there is significant heterogeneity across studies we should not combine these trials in a metaanalysis. Instead, we should conclude that the treatment effect cannot be considered 'generic', but depends on the type of subjects treated or on specifics of the intervention. Results of the meta-analysis are shown in Figure 1 and show no significant survival benefit for autotransplants.
How often are results of meta-analyses of RCTs correct? Answering this assumes that the correct answer is known. In one study, results of meta-analyses performed before data from a large RCT were available were compared with results of the large RCT whose conclusion was assumed to be correct. 25 About one-third of the time results of the RCT were discordant with results of the prior meta-analysis. Both false positives and negatives were detected. Similar analyses are reported by others with error rates varying from 10 to 40%. 26 These data suggest results of metaanalyses, especially in a field such as transplants where there are few large RCTs, are unlikely to completely resolve controversies regarding therapy strategies.
Experts in meta-analysis admit the limitations of this approach; some consider it an oversimplification of complex data. In considering results of meta-analyses, it is important to separately evaluate the quality of the studies included and the consistency (or inconsistency) of their results. Equally important is transparency in how studies were selected for inclusion. In doing so, the reviewer must rely on his or her expert opinion. Not unexpectedly, different experts may seemingly reach different conclusions Figure 1 Meta-analysis of the ratio of overall survival probabilities. See Nathan et al. 72 for details.
about the value of a specific meta-analysis. How to determine whether there are true differences in expert opinion on this and other issues and quantify this is discussed below. Another issue is whether results of ODBs (discussed below) should be included in meta-analyses typically restricted to data from RCTs? In a random analysis of meta-analyses from the Cochrane Collaboration, about one-third of meta-analyses had data from two RCTs. 27 Some data suggest adding data from ODBs to these metaanalyses of RCTs is useful. 28 This is especially so if the anticipated benefits of adding data from ODBs exceed the anticipated risks by a substantial margin. For example, when there are few, if any, large RCTs and/or when there is substantial variability and/or biases in these trials. This situation, as discussed, applies to most clinical trials in blood cell and BM transplants. A detailed discussion of ODBs follows.
Finally, a fundamental limitation of most meta-analyses is the lack of subject-level data. This limits the ability to assure comparability of seemingly similar studies, to explore variables correlated with outcomes and to combine results of RCT and ODB studies among others.
Observational studies 'Candy Is Dandy But liquor Is quicker'. Ogden Nash Well, perhaps not quicker, but a reasonable alternative with a similarly reliable outcome.
Features
Several types of observational studies can also be used to determine whether a new therapy is better than a current therapy including (1) controlled cohort studies; and (2) case-control studies. Here, we focus on use of ODBs in the context of determining therapy-benefit.
The necessary starting point for using ODBs is a highquality data set. High-quality ODBs should contain subjects-level data. Consecutiveness, accuracy and completeness of reporting must be known. Consensus on requirements for high-quality ODBs was recently published. 29 The potential advantages of high-quality ODBs over experimental studies, including RCT, in determining therapybenefit are severalfold. The most important is the vastly larger numbers of subjects available for analyses. This increases the power of analyses but poses specific problems (see below). Also, subjects are more diverse in ODBs than in RCTs increasing potential applicability and generalizability of conclusions. Less precisely defined therapy approaches are often used, for example, several techniques of T-cell-depletion may be tested. The advantage of this is to allow a more generic conclusion such as whether T-celldepletion is effective, as well as to explore whether these various techniques have similar effects. ODB studies are far less costly than RCTs.
Limitations
There are important limitations to ODBs in the context of determining therapy-benefit. For example, heterogeneity of subject-, disease-and therapy-related variables makes it important to ensure comparability of subjects in the therapy-arms. Although adjustments can be made for known prognostic variables, there can be no such adjustment for unknown variables or variables that might operate in a new therapy setting. This is probably the most important difference between ODBs and large RCTs where comparability of subjects in therapy arms is not ensured by random assignment. Also, less precisely specified therapy approaches may result in combining approaches of differing efficacy. For example, an effective technique of T-celldepletion may be combined with an ineffective technique resulting in an incorrect conclusion regarding efficacy. Because of this, negative ODB studies are less important than positive ODB studies because the positive studies may be a conservative estimate of effect magnitude.
Another limitation of ODBs is that diagnostic criteria and observation schedules vary between centers. These can result in important ascertainment biases. For example, different centers may use different criteria to diagnose leukemia relapse (5% myeloblasts at one center and 10% at another). Also, BM examinations may be performed at different frequencies at different centers. Another issue is time-to-treatment biases. For example, the waiting time to find an HLA-identical unrelated donor is substantially longer than that needed to identify an HLA-identical sibling. If an ODB compares results of transplants using these two types of donors, outcomes in the unrelated donor cohort may be artificially altered because subjects with unstable remissions may relapse before a donor is found and therefore not enter the ODB. Other selection biases also operate: clinicians may preferentially use a specific therapy more in one group of subjects than another. If the variable(s) leading to these selection biases are known, they can be adjusted for. However, some variables leading to selection biases may be unknown or unrecorded. Studies using ODBs are restricted to the data being routinely collected, and it is difficult to obtain additional nonstandard data on patients. This may make ODB studies difficult to implement in certain settings. Finally, similar to RCTs, ODB studies are often behind the times in a field because of the need to accumulate sufficient numbers of subjects with adequate follow-up.
The fundamental criticism of observational studies is that unrecognized confounding factors may distort results. This is true. However, the common belief that confounding with subsequent distortion is common and unpredictable is incorrect in most instances (see below).
How do results of RCTs and ODBs compare?
Clinicians can be more certain a therapy strategy is correct when their decision is based on concordant results of several large RCTs. However, as discussed, these data are often unavailable. In this instance, analyses from ODBs may help. Several recent studies compared results of RCTs and ODBs. Data from the first study carried out for five common medical indications are shown in Figure 2 . 30 Analysis of the point estimates for therapy-effect shows remarkable similarity between RCTs and ODBs. This figure also shows the heterogeneity of results of RCTs (discussed above) and the relatively smaller range of point estimates of ODBs. A second study compared results of RCTs and ODBs for 19 diverse treatment settings. 31 Estimates of treatment effects were concordant in 17; in only 2 settings was the magnitude of the effect in the ODBs outside the 95% confidence interval for the RCTs. A third study compared results of ODBs and RCTs in eight settings. 32 Concordant results were found in seven. In a fourth study, results of RCTs and ODBs were compared in 45 settings. 26 Odds ratios were similar for both techniques (about 85% of comparisons) despite substantial betweenstudy heterogeneity for both (greater for ODBs than RCTs). Discordant results were found for o10% of prospective studies. A fifth study found concordant conclusions in six of eight settings compared. 33 Combining these data, estimates of treatment effect from ODBs and RCTs were concordant in 490% of setting. In the rare discordances, ODBs estimated greater benefit than seemingly comparable RCTs. Often the magnitude of discordance in estimating treatment effect correlates with study quality: low for high-quality studies but high for lowquality studies. 9, 34 What should clinicians conclude when results of RCTs and ODBs are discordant? First, they need to consider whether the subjects and therapies tested are comparable, whether follow-up is comparable and whether similar study end-points were used. Were similar subjects studied? ODBs almost always include more diverse subjects than RCTs. Were the therapies similar? Again, ODBs almost always include more diverse doses and schedules of drugs than RCTs. Was follow-up comparable? Because ODBs almost always have substantially longer follow-up than RCTs, they are more likely to use a survival end-point than RCTs, which may focus on disease-free survival or freedom-fromrelapse or -progression. A reasonable conclusion is that ODBs and RCTs will likely reach concordant conclusions when the magnitude of bias inherent in ODBs is small compared with the variability and biases inherent to RCTs (choice of study subjects, disease, disease states, drug doses and schedules and so on). 28 Although an extensive review of the issue of disagreement between RCTs and ODBs is beyond our scope, a recent example of concordances and discordances is the question whether blood cells or BM grafts are better. Several RCTs analyzed outcome of transplants using blood cell vs BM grafts in adults with hematologic disorders. One trial had 39 subjects with diverse hematologic cancers receiving HLA-identical sibling grafts. 35 The conclusion was there was no difference in acute or chronic GvHD or survival. Leukemia relapses were fewer with blood cell vs BM grafts. Power of this study to exclude an increase in GvHD or survival was not stated nor was it possible to analyze effects in different cancers or disease states, such as early or advanced. A second RCT of 172 subjects was limited to those aged between 12 and 55 years, also with diverse hematologic cancers, receiving grafts from HLAidentical related donors (not just from siblings 36 ). It also found no increase in acute or chronic GvHD and no change in survival but better disease-free survival with blood cell grafts. A third RCT in those between 15 and 55 years old was limited to 350 subjects with early leukemia receiving grafts from HLA-identical siblings. 37 It reported significant increases in acute and chronic GvHD; survival and leukemia-free survival (LFS) were comparable.
Data from these RCTs show the difficulty in concluding whether or not blood cell grafts are better than BM grafts. For example, the two larger studies were limited to persons o55 years old but had different starting ages and different donor specifications. Second, results were contradictory even in the two large studies: one found no increase in acute or chronic GvHD, whereas the second found increases in both. Two studies included subjects with early and advanced hematologic cancers, whereas one study had only for details.
Observational databases and expert opinion in transplants RP Gale et al subjects with early leukemia. Furthermore, in a study of early leukemia there was no distinction between persons with acute leukemias and those with CML. Hence, it is not possible to know, for example, if these seemingly disparate results are because blood and BM grafts operate differently in different diseases, ages and/or disease states.
The question of blood cell vs BM grafts has also been studied using ODBs. The CIBMTR and the European Group for Blood and Marrow Transplantation (EBMT) collected data on transplant outcomes of 706 subjects receiving HLA-identical sibling blood cell or BM grafts regardless of whether subjects were enrolled in an RCT. 38, 39 This study found increased chronic, but not acute, GvHD. LFS was higher after blood cell grafts in advanced CML but lower for early CML. LFS was similar with both types of grafts in persons with acute leukemia regardless of leukemia stage.
A second ODB study from the CIBMTR and National Marrow Donor Program (NMDP) compared blood cell and BM grafts in 917 subjects with leukemia and myelodysplastic syndrome receiving grafts from HLAmatched unrelated donors aged 18-60 years. 40 Acute and chronic GvHD were more common after blood cell grafts. There was no difference in survival or LFS, including persons with advanced leukemia. A third ODB study by the IBMTR of 773 persons with acute leukemia aged between 8-20 years also compared blood cell and BM grafts from HLA-identical sibling donors. 41 Acute and chronic GvHD, LFS and survival were all worse after blood cell grafts. A fourth CIBMTR study using an ODB of 692 subjects with aplastic anemia found more chronic GvHD and worse survival in younger persons (but not older persons) receiving blood cell vs BM grafts from HLA-identical siblings. 42 Data from these ODB studies indicate complexity of the seemingly simple question of whether blood cell or BM grafts are better. There are clear interactions between grafttype and age, donor-type, diagnosis and disease stage. An RCT to sort out these interactions would need to be huge and include diverse types of subjects. No such trial is reported or contemplated. The ODB studies involved more than 3000 subjects. They provide important clues to the complexity of this seemingly simple question. Ideally, conclusions from the ODB studies would be tested in RCT. This seems exceedingly unlikely.
These data suggest results of RCTs, although useful, are often incomplete and/or contradictory. These studies also typically have relatively brief follow-up. There are several circumstances when data from ODBs may be more useful to the clinician and often more definitive than RCTs because the benefit achieved by analyzing large numbers of subjects with diverse features exceeds potential biases. Examples include: (1) when RCTs are not feasible because of small numbers of subjects; (2) when several small RCTs do not reach a definitive conclusion or reach contradictory conclusions; (3) when long-term follow-up is of interest and (4) when an RCT is not feasible because an unresolved issue is no longer the focus of clinical research interest. In areas of current clinical interest, clinicians are certainly most comfortable when a conclusion is supported by concordant outcomes of RCTs and ODBs. Do we always need data from one or more RCTs to make a reasonable intervention recommendation? Not every intervention requires data from an RCT to make a reasonable intervention recommendation. Consider, for example, leaping from the Empire State building without a parachute. Is a parachute useful? 43 We have no RCTs dealing with this question. Nor are there structured, evidence-based reviews. Occasionally, persons survive falls from great heights. Also, persons wearing parachutes sometimes die because the chute fails to deploy quickly enough or because of a technical failure (or errant power line). Even comments from people queried en route (for example, as the jumpers pass the 11th floor) can be misleading: 'so far, so good'. Does this mean we should hold-off recommending parachutes when leaping off tall buildings? Need we await results of RCTs, structured reviews and the like? No. (Persons wishing to register for such an RCT, kindly contact the authors.)
Thinking about clinical problems 'Most people would rather die than think. In fact, they do so'.
Bertrand Russell
Creative thinking is a great asset in trying to solve complex clinical questions. A rarely discussed consequence of large RCTs is the near cessation of creative thinking once a study is formulated. At this point, clinicians focus attention on effecting the study and analyzing the results. They stop considering whether the therapies being compared are the best options for each subject entering the study. The payoff is, of course, a definitive comparison of the therapies; the price, not thinking about the issue for a long interval. In contrast, physicians are forced to estimate the best therapy for each subject when these persons are not part of a clinical trial. The payoff is more thinking; the price, no definitive comparison of alternative therapies. Which approach is a better investment in the long-term is unknown.
New uses of ODBs
Data from ODBs can be used in several creative ways. For example, several studies from the CIBMTR compared outcomes of transplants from an ODB with data from RCTs of chemotherapy. 44 These comparisons are complex and require adjustment for many subject-and diseaserelated variables and for selection biases. Nevertheless, results of these combined comparisons are typically concordant with results of similar RCTs. Data from ODBs have also been used by the CIBMTR and others to simulate RCT using propensity score analyses. Again, results of these analyses are typically concordant with those of RCTs. 45 
Expert opinion
Why bother with group expert opinion? Francis Galton was apparently surprised when he noted that the averaged guesses of a crowd at a county fair estimated the weight of an ox more accurately than the estimate of any one expert butcher (recounted in Surowiecki 46 ). There are many similar examples of the advantage of aggregated group opinions over individual judgments. This advantage of quantifying a diversity of opinions hinges on several factors: (1) each person should have comparable data; (2) each opinion should be independent; (3) each person should use personal knowledge and (4) there needs to be a structured mechanism for turning private judgments into an aggregated estimate.
What happens when experts disagree? Some scientists regard expert opinion as the highest level of evidence in therapy decision-making. This is because (hopefully) experts' calculi include diverse lower order data, including biological plausibility, case reports and series, personal experiences and data from RCTs, ODBs and meta-analyses thereof. However, not everyone shares this view. Some consider expert opinion unreliable. In the US Public Health Service Preventative Services Task Force hierarchy of evidence and elsewhere, expert opinion is judged the lowest-level type of evidence. 18, 20 Likewise in the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) system (http://clinicalevidence. bmj.com/ceweb/about/about-grade.jsp). How can we explain these discordant views?
One problem with expert opinion that may explain its low ranking is that different experts seem to reach different conclusions about the best therapy for a specific person or disease state. Or do they? As we will discuss, experts rarely disagree on substantial issues. Most disagreements can be traced to a few variables: (1) different data-sets; (2) different perceptions about the target subject and (3) different perceptions about the question being posed (is it the best outcome, the most cost-effective, the most interesting research question and so on?). When these ambiguities are removed, experts rarely disagree. This, of course, does not mean their consensus opinion is correct: there was once agreement the sun circled the earth! Panel composition. Determining the appropriate panel members is fundamental to success of the consensus process. 47 Panels composed entirely of believers or nonbelievers in a new therapy are unlikely to reach a balanced, reproducible conclusion because of confirmation bias (see above). Moreover, panels of believers and non-believers may fail to reach consensus because of attitude bias (also see above). In considering panel composition, it is important to replicate the target environment in which therapy decisionmaking will occur. For example, it may be important to have representation if the conclusions are to be accepted nationally or internationally. Considerable data show substantial geographical variation in the use of radiation therapy vs surgery vs watch-and-wait in managing prostate cancer in comparable subjects (for example, in Krupski et al. 48 ). Often, these geographical variations are not explainable by appropriate or inappropriate technology use. 49 Also, Americans and Europeans often view new therapies from different perspectives driven by issues other than efficacy, such as cost and resource use. It is important that proponents and opponents of a new therapy be represented. Panel size is also important: panels of fewer than nine members rarely have reproducible results; larger panels are unwieldy and expensive.
Consensus methods
Data set. Panelists should be informed of all data relevant to the topic being considered. Published data can be retrieved, evaluated (for example, for level of evidence) and summarized. Inclusion of data from RCTs, ODBs and meta-analyses thereof is important. Several systems for ranking the quality of evidence are widely used (for example, Preventive Services Task Force  18 and Harbour  and Miller   20 ). There are factors that limit these rankings, such as publication biases (discussed above). Above, we discussed disagreements over the quality of evidence rankings of data inputs such as ODBs and expert opinion. A more important challenge problem is ensuring all panelists know unpublished data, including abstracts, meeting reports and personal experiences. This can be accomplished in interactive sessions (see below).
Defining the subject and question. Many seemingly discordant opinions among experts arise from failure to precisely define the question(s). For example, when asked which of two therapies is more appropriate, experts may envision rather different subjects with different diseaserelated prognostic variables and prior therapies. This can be overcome by precisely defining disease-related prognostic variables (such as age and sex) by hierarchical permutation of relevant variables followed by ranking of precisely defined subjects. Experts can also be polled preranking to determine which variables they believe are needed to estimate the best therapy. Typically, experts identify fewer than 10 variables, often fewer than 5, which influence their decision-making. As expected, lists of variables from different experts often overlap substantially. Examples include age, sex, disease stage, performance score, prior therapy response and response duration. However, recursive partitioning analyses of expert opinion post-ranking often show experts use only a subset of the variables they believed were important pre-ranking.
Another requisite for success is a clearly defined question. Usually this is what the best therapy is for the subject being considered. Experts need to be explicitly told not to consider collateral issues such as cost, resource use and societal values (such as answering a question that benefits future subjects but not the subjects being considered). ); a detailed discussion is beyond our scope. At one extreme, experts independently review data and the sum of their opinions is expressed quantitatively or qualitatively, ideally with a description of the variance. Other techniques involve bringing experts together in a structured or unstructured format. Again, the sum of their opinions can be expressed quantitatively or qualitatively. Unfortunately, there are few data on internal and external validation of these processes. For example, how many experts should be included, should there be one or several sessions, will individual opinions be confidential and are results expressed quantitatively or qualitatively? Other techniques are more elaborate. For example, Delphi consensus panels use defined numbers of panelists in multiple iterative, interactive sessions combined with anonymous voting and sophisticated data analyses. [51] [52] [53] [54] [55] [56] The Delphi-panel technique yields specific criteria of appropriateness that can be used as the basis for treatment guidelines.
Consensus techniques

Internal and external validation
Reliability of these expert consensus techniques requires internal and external validation. There are few data addressing this issue. For example, most techniques have not been rigorously tested for internal validity: are results of a consensus panel reproducible if carried out by the same panel 6 months or 1 year later? More importantly, are they reproducible when the same data are concurrently reviewed by a different expert panel? An exception is Delphi panels where there are considerable data indicating recommendations of similarly constituted panels are reproducible when concurrent panels review similar data. 57 One test of external validity is whether recommendations of Delphi analyses are concordant with subsequently performed RCTs. Recent analyses indicate reasonably high concordance. 58 Other data are likewise supportive. 59 Similar tests of external validity of other consensus methods are less often reported.
Expert opinion in transplants
Several expert panels have evaluated appropriateness of blood cell and BM transplants compared with alternative therapies. They have also sometimes evaluated transplant techniques, such as whether blood cell or BM grafts are better. Examples include expert panels from the National Cancer Center Network (NCCN), American Society of Blood and Marrow Transplantation (ASBMT). [60] [61] [62] [63] [64] [65] These panels performed structured evidence-based reviews and made consensus recommendations of graded strength. 20 Mechanisms of panel selection and process for quantifying consensus were not specified. There are also several Delphi consensus studies of transplants. [66] [67] [68] [69] [70] [71] It is interesting and informative to consider whether these diverse consensus techniques reach similar conclusions and then to compare these conclusions to those of meta-analyses of RCTs and ODBs. An example is the previously discussed issue of the possible efficacy of autotransplants vs chemotherapy in persons with AML in first remission. Two meta-analyses of six RCTs published in 2004 concluded that there was no survival advantage for autotransplants vs chemotherapy. 72, 73 A subsequent seventh RCT and updated meta-analysis also found no survival benefit. 74 A Delphi consensus panel analysis published 5 years earlier concluded that there was no survival advantage for autotransplants over chemotherapy (with the possible exception of persons with adverse risk cytogenetics, a variable not considered in the metaanalyses). 67, 70 A structured evidence-based expert panel report published 4 years after these meta-analyses also concluded that there was no survival benefit for autotransplants over chemotherapy. 64 Finally, an as yet unpublished analysis from the CIBMTR also found no survival benefit. These data show a concordance of opinions. They also show that expert panels reach conclusions similar to those provided from meta-analysis of RCTs and ODBs. There are several other examples of similar high levels of concordance in the transplant arena. On the basis of these data, we propose that quantification of expert opinion, especially using high-structure techniques such as the Delphi consensus method, is often correct in determining whether a new therapy is effective.
Limitations
Added to the cautions we discuss above is another important and interesting limitation, partially related to, but distinct from confirmation bias: experts are easier to fool than non-experts. The cause is that they jump to unwarranted conclusions because they see immediately the direction an issue is headed and because they tend to focus on subtleties rather than larger issues (summarized in Dolnick 75 ). For example, 54 wine experts were given red wines to evaluate, several of which were really white wines with a tasteless red dye added. None of the experts detected the subterfuge: they were off considering the subtleties of red wines such as terroir, bouquet, tannins and the like. In contrast, non-experts were more likely to correctly identify the red wines as white because they were not so easily subverted. In a similar vein, several fish experts claimed to be able to distinguish between the unappealing Patagonian toothfish and the ever popular Chilean sea bass. They are the same fish. That said, careful and critical quantification of expert opinion can be useful, especially if there is concordance with conclusions from RCTs and ODBs.
Conclusions
Although large RCTs are rightly considered the gold standard study design, many RCTs in the transplant setting have modest sample size and may require other compromises such as pooling of treatment regimens or subjects to increase sample sizes. This can lead to inconsistency in results across multiple trials. Reliance on ODBs and structured quantification of expert opinion provides alternatives, which have strengths that complement those of typical RCTs including increasingly diverse subjects, greater generalizability, lower cost and the ability to examine consistency of treatment effects. Although there is greater potential for bias in ODB-based analyses, several studies indicate frequent concordant conclusions for RCTs, ODBs, meta-analyses and structured quantification of expert opinion. Care must be taken: there are several important exceptions such as the effect of hormone replacement therapy in postmenopausal women. We suggest ODBs and structured quantification of expert opinion have an important role in answering therapy questions in blood cells and bone marrow transplantation and that results of these studies should not be discounted simply because they are not RCTs. There should also be efforts to improve design and conduct of RCTs. 76 We need all the help we can get in making complex therapy decisions.
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